Kailera Therapeutics, Inc. (KLRA)

NASDAQ: KLRA · Real-Time Price · USD

26.00

+10.00 (62.50%)

At close: Apr 17, 2026, 4:00 PM EDT

25.99

-0.01 (-0.04%)

After-hours: Apr 17, 2026, 7:59 PM EDT

62.50% (1D)

Market Cap	3.07B
Revenue (ttm)	n/a
Net Income	-148.96M
EPS	-7,819.98
Shares Out	117.95M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	8,114,314
Open	26.00
IPO Price	16.00
Day's Range	23.70 - 27.50
52-Week Range	16.00 - 27.50
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About KLRA

Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions. The company develops clinical- and preclinical-stage therapies, with a product pipeline that includes injectable peptides, oral peptides, and oral small molecules. Key programs include KAI-9531, an injectable GLP-1/GIP receptor dual agonist; KAI-7535, an oral small molecule GLP-1 receptor agonist; and KAI-4729, an injectable GLP-1/GIP/glucagon receptor tri-agonist. Kailera Therapeutics holds exclusive rights... [Read more]

Industry Biotechnology

Sector Healthcare

IPO Date Apr 17, 2026

Employees 145

Stock Exchange NASDAQ

Ticker Symbol KLRA

Website https://www.kailera.com

Full Company Profile